Abstract
A method of preventing or treating xenotransplant rejection in a subject in need thereof is disclosed. The method comprises administering a therapeutically effective amount of alpha-1-antitrypsin (AAT) in combination with a therapeutically effective amount of an anti-CD8 antibody or an antigen binding fragment thereof.
| Original language | English |
|---|---|
| Patent number | US10086070B2 |
| State | Published - 1 Oct 2018 |
Fingerprint
Dive into the research topics of 'Combined Therapy of Alpha-1-Antitrypsin and Temporal T-Cell Depletion for Preventing Graft Rejection'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver